Search

Your search keyword '"Nandy, Indrani"' showing total 34 results
Start Over Author "Nandy, Indrani"
34 results on '"Nandy, Indrani"'

9. A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Patients With Major Depressive Disorder

Author

Clayton, Anita, primary, Lasser, Robert, additional, Nandy, Indrani, additional, Sankoh, Abdul, additional, Campbell, Andrew, additional, Werneburg, Brian, additional, Silber, Christopher, additional, Jonas, Jeffrey, additional, Kanes, Stephen, additional, and Gunduz-Bruce, Handan, additional

Published
2020
Full Text
View/download PDF

15. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial

Author

Toglia, Marc R., Serels, Scott R., Laramee, Christine, Karram, Mickey M., Nandy, Indrani M., Andoh, Masakazu, Seifeldin, Raafat, and Forero-Schwanhaeuser, Sergio

Subjects
Urinary incontinence -- Care and treatment, Urinary incontinence -- Patient outcomes, Urinary incontinence -- Research, Solifenacin -- Dosage and administration, Solifenacin -- Research, Quality of life -- Health aspects, Quality of life -- Research, Health
Published
2009

16. T111. Patient-Reported Health-Related Quality of Life Correlates Inversely With Depressive Symptoms in a Pivotal Trial of SAGE-217 in Major Depressive Disorder

Author

Suthoff, Ellison, primary, Gunduz-Bruce, Handan, additional, Silber, Christopher, additional, Arnaud, Alix, additional, Lasser, Robert, additional, Sankoh, Abdul, additional, Li, Haihong, additional, Nandy, Indrani, additional, Bonthapally, Vijay, additional, Werneburg, Brian, additional, Jonas, Jeffrey, additional, Doherty, James, additional, and Kanes, Stephen, additional

Published
2019
Full Text
View/download PDF

20. Dutasteride Treatment Over 2 Years Delays Prostate-specific Antigen Progression in Patients with Biochemical Failure After Radical Therapy for Prostate Cancer: Results from the Randomised, Placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS)

Author

Schröder, Fritz, primary, Bangma, Chris, additional, Angulo, Javier C., additional, Alcaraz, Antonio, additional, Colombel, Marc, additional, McNicholas, Tom, additional, Tammela, Teuvo L., additional, Nandy, Indrani, additional, and Castro, Ramiro, additional

Published
2013
Full Text
View/download PDF

22. Corrigendum to “The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study” [Eur Urol 2010;57:123–31]

Author

Roehrborn, Claus G., primary, Siami, Paul, additional, Barkin, Jack, additional, Damião, Ronaldo, additional, Major-Walker, Kim, additional, Nandy, Indrani, additional, Morrill, Betsy B., additional, Gagnier, R. Paul, additional, and Montorsi, Francesco, additional

Published
2010
Full Text
View/download PDF

23. The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study

Author

Roehrborn, Claus G., primary, Siami, Paul, additional, Barkin, Jack, additional, Damião, Ronaldo, additional, Major-Walker, Kim, additional, Nandy, Indrani, additional, Morrill, Betsy B., additional, Gagnier, R. Paul, additional, and Montorsi, Francesco, additional

Published
2010
Full Text
View/download PDF

25. Tobacco use among male high school athletes

Author

Davis, Terry C., primary, Arnold, Connie, additional, Nandy, Indrani, additional, Bocchini, Joseph A., additional, Gottlieb, Anita, additional, George, Ronald B., additional, and Berkel, Hans, additional

Published
1997
Full Text
View/download PDF

32. Surgical and nonsurgical management of primary and...

Author

Zibari, Gazi B., Riche, Andrew, Zizzi, Henry C., McMillan, Robert W., Aultman, Donnie F., Boykin, Kevin N., Gonzalez, Enrique, Nandy, Indrani, Dies, David F., Gholson, Charles F., Holcombe, Randall F., and McDonald, John C.

Subjects
*LIVER surgery, *LIVER tumors, *LIVER diseases
Abstract

Investigates the management of primary and metastatic liver tumors. Frequency of abnormal liver function tests in metastatic liver cancer; Frequency of sings and symptoms in metastatic hepatic lesions and primary malignant liver cancer; Survival probability of surgical and non-surgical patients; Complications of patients undergoing resection for primary or metastatic liver tumors.

Published
1998

33. The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study

Author

Indrani Nandy, Paul Siami, Jack Barkin, Ronaldo Damião, R. Paul Gagnier, Francesco Montorsi, Kim Major-Walker, Claus G. Roehrborn, Betsy Morrill, Roehrborn Claus, G., Siami, Paul, Barkin, Jack, Damiao, Ronaldo, Major Walker, Kim, Nandy, Indrani, Morrill Betsy, B., Gagnier R., Paul, and Montorsi, Francesco

Subjects
Male, Tamsulosin, medicine.medical_specialty, Time Factors, Urologic Surgical Procedures, Male, Combination therapy, Urology, Prostatic Hyperplasia, Kaplan-Meier Estimate, Risk Assessment, Severity of Illness Index, chemistry.chemical_compound, 5-alpha Reductase Inhibitors, Double-Blind Method, Lower urinary tract symptoms, Risk Factors, medicine, Clinical endpoint, Humans, Enzyme Inhibitors, Adrenergic alpha-Antagonists, Aged, Proportional Hazards Models, Sulfonamides, Urinary retention, business.industry, Dutasteride, Middle Aged, Urinary Retention, medicine.disease, Surgery, Treatment Outcome, Tolerability, chemistry, Italy, Azasteroids, North America, Disease Progression, International Prostate Symptom Score, Drug Therapy, Combination, medicine.symptom, business, Brazil, medicine.drug
Abstract

Background: Combination therapy with dutasteride and tamsulosin provides significantly greater benefit than either monotherapy for various patient-reported outcomes in men with moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and prostatic enlargement. Objective: To investigate whether combination therapy is more effective than either monotherapy in reducing the relative risk for acute urinary retention (AUR), BPH-related surgery, and BPH clinical progression over 4 yr in men at increased risk of progression. Design, setting, and participants: The Combination of Avodart (R) and Tamsulosin (CombAT) study was a 4-yr, multicenter, randomised, double-blind, parallel-group study in 4844 men >= 50 yr of age with a clinical diagnosis of BPH, International Prostate Symptom Score >= 12, prostate volume >= 30 cm(3), prostate-specific antigen 1.5-10 ng/ml, and maximum urinary flow rate (Q(max)) >5 and = 125 ml. Intervention: Oral daily tamsulosin, 0.4 mg; dutasteride, 0.5 mg; or a combination of both. Measurements: The 4-yr primary end point was time to first AUR or BPH-related surgery. Secondary end points included BPH clinical progression, symptoms, Q(max), prostate volume, safety, and tolerability. Results and limitations: Combination therapy was significantly superior to tamsulosin monotherapy but not dutasteride monotherapy at reducing the relative risk of AUR or BPH-related surgery. Combination therapy was also significantly superior to both monotherapies at reducing the relative risk of BPH clinical progression. Combination therapy provided significantly greater symptom benefit than either monotherapy at 4 yr. Safety and tolerability of combination therapy was consistent with previous experience with dutasteride and tamsulosin monotherapies, with the exception of an imbalance in the composite term of cardiac failure among the three study arms. The lack of placebo control is a study limitation. Conclusions: The 4-yr CombAT data provide support for the long-term use of dutasteride and tamsulosin combination therapy in men with moderate-to-severe LUTS due to BPH and prostatic enlargement. Clinicaltrials.gov identifier: NCT00090103 (http://www.clinicaltrials.gov/ct2/show/NCT00090103). (C) 2009 European Association of Urology. Published by Elsevier B. V. All rights reserved.

Published
2010

34. Effects of zuranolone on next-day simulated driving in healthy adults.

Author

Dunbar J, Morelli G, Jain R, Vaudreuil C, Nandy I, Ona V, Moseley MK, Levin S, and Kay G

Abstract

Rationale: Zuranolone is an oral positive allosteric modulator of GABA A receptors. Due to its central nervous system (CNS) activity, zuranolone may impact activities requiring complex cognition, including driving., Objective: Evaluate the effect of zuranolone on simulated driving performance., Methods: In this randomized, double-blind, active- and placebo-controlled, four-period crossover study, treatments included once-nightly zuranolone 50 mg on days 1-7, zuranolone 50 mg on days 1-6 and zuranolone 100 mg on day 7, zopiclone 7.5 mg on days 1 and 7, and placebo on days 1-7. Driving was assessed using a validated simulator. Primary endpoint was standard deviation of lateral position (SDLP), evaluated 9 h post-dose on days 2 and 8. Secondary endpoints included additional driving assessments, cognitive tests, pharmacokinetics, and safety., Results: Healthy adults (N = 67) enrolled and received ≥ 1 dose. Zuranolone 50 mg increased SDLP versus placebo on days 2 (least squares mean difference [LSMD]: 7.4 cm; p < 0.0001) and 8 (LSMD: 4.6 cm; p = 0.0106). Zuranolone 100 mg evoked a larger increase in SDLP versus placebo on day 8 (LSMD 18.9 cm; p < 0.0001). Reduced performance in other driving assessments and cognition were observed with zuranolone 50 mg on day 2; many resolved by day 8. Despite the SDLP observations, most participants judged themselves capable of driving. Frequent adverse events (≥ 20%) were CNS-related; most were mild/moderate., Conclusion: Zuranolone impaired simulated driving and reduced cognitive function versus placebo 9 h after administration. Although many impairments resolved after 7 days of dosing, driving remained impaired. These results may inform prescriber decision-making., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results